New and emerging therapies in psoriasis.

Seminars in cutaneous medicine and surgery

Volumn 33, Issue 2 Suppl 2, 2014, Pages

  Leonardi, Craig L ^a   Gordon, Kenneth B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; BRODALUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; MONOCLONAL ANTIBODY; SECUKINUMAB; TILDRAKIZUMAB; TOFACITINIB; USTEKINUMAB;

ARTICLE; DRUG ANTAGONISM; HUMAN; INTERLEUKIN-12/23 INHIBITORS; INTERLEUKIN-17 INHIBITORS; JAK; JANUS KINASE INHIBITORS; PHOSPHODIESTERASE-4 INHIBITORS; PSORIASIS; PSORIASIS TREATMENT; TUMOR NECROSIS FACTOR INHIBITORS;

APREMILAST; BRODALUMAB; INTERLEUKIN-12/23 INHIBITORS; INTERLEUKIN-17 INHIBITORS; IXEKIZUMAB; JAK; JANUS KINASE INHIBITORS; PHOSPHODIESTERASE-4 INHIBITORS; PSORIASIS TREATMENT; SECUKINUMAB; TILDRAKIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITORS; USTEKINUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS;

MLCS; MLOWN;

EID: 84905588626     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.12788/j.sder.0071     Document Type: Article

References (0)